Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,686 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative flow ratio versus fractional flow reserve for Heart Team decision-making in multivessel disease: the randomised, multicentre DECISION QFR trial.
Asano T, Tanigaki T, Hoshino M, Yasunaga M, Nonaka H, Emori H, Katagiri Y, Miyazaki Y, Sotomi Y, Kogame N, Kuramitsu S, Saito A, Miyata K, Takaoka Y, Kanie T, Yamasaki M, Yoshino K, Wakabayashi N, Ouchi K, Kodama H, Shiina Y, Tamaki R, Nishihata Y, Masuda K, Suzuki T, Reiber JHC, Okamura T, Higuchi Y, Kakuta T, Misumi H, Abe K, Komiyama N, Tanabe K, Matsuo H, Qfr Investigators OBOTD. Asano T, et al. Among authors: masuda k. EuroIntervention. 2024 May 10;20(9):561-570. doi: 10.4244/EIJ-D-23-00674. EuroIntervention. 2024. PMID: 38726719 Clinical Trial.
Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
Tamura K, Okuma Y, Nomura S, Fukuda A, Masuda K, Matsumoto Y, Shinno Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Tamura K, et al. Among authors: masuda k. J Cancer Res Clin Oncol. 2024 Apr 26;150(4):216. doi: 10.1007/s00432-024-05649-x. J Cancer Res Clin Oncol. 2024. PMID: 38668936 Free PMC article.
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y. Miyakoshi J, et al. Among authors: masuda k. Lung Cancer. 2024 May;191:107788. doi: 10.1016/j.lungcan.2024.107788. Epub 2024 Apr 6. Lung Cancer. 2024. PMID: 38593478
2,686 results